11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 23.07.2026 Expectation: 1090 pips
USDJPY sell-off targets 161.030 amid lower market volatility and higher inflation expectations in Japan
Today at 11:09 AM 9
Period: 16.08.2026 Expectation: 285 pips
Sell ETHUSD with $1,500 in sight
Today at 09:34 AM 12
Period: 30.07.2026 Expectation: 100 pips
Invest in SPX on slower US inflation
Today at 09:34 AM 20
Gold buy
Period: 23.07.2026 Expectation: 170 pips
Go long on gold with $4,200 target as institutions accumulate
Today at 06:49 AM 28
Period: 29.07.2026 Expectation: 1800 pips
Selling EURUSD down to 1.12500
Yesterday at 11:26 AM 38
Period: 31.07.2026 Expectation: 150 pips
Buying Brent crude up to $78.50 per barrel
Yesterday at 10:52 AM 36
Go to forecasts